• The application of Hadoop in structural bioinformatics 

  Alnasir, JJ; Shanahan, HP (Oxford University Press (OUP), 2018-11-20)
• Cyclisation of Cell-Penetrating PDZ-Binding Peptides Directed to PSD95 

  Dabhi, S; Duberly, K; Alnasir, J; Wijesiriwardana, N; Austen, B (2019-05-01)
• Visualizing the complex functions and mechanisms of the anaphase promoting complex/cyclosome (APC/C). 

  Alfieri, C; Zhang, S; Barford, D (2017-11)

  The anaphase promoting complex or cyclosome (APC/C) is a large multi-subunit E3 ubiquitin ligase that orchestrates cell cycle progression by mediating the degradation of important cell cycle regulators. During the two ...
• Advances in Targeted Alpha Therapy for Prostate Cancer. 

  De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; O'Sullivan, JM; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O (2019-08-16)

  BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while ...
• Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement. 

  Merriel, SWD; Hetherington, L; Seggie, A; Castle, JT; Cross, W; Roobol, MJ; Gnanapragasam, V; Moore, CM; Prostate Cancer UK Expert Reference Group on Active Surveillance (2019-07)

  OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis ...
• Identification of single nucleotide variants using position-specific error estimation in deep sequencing data 

  Kleftogiannis, D; Punta, M; Jayaram, A; Sandhu, S; Wong, SQ; Gasi Tandefelt, D; Conteduca, V; Wetterskog, D; Attard, G; Lise, S

  <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Targeted deep sequencing is a highly effective technology to identify known and novel single nucleotide variants (SNVs) with many ...
• Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. 

  Kleftogiannis, D; Punta, M; Jayaram, A; Sandhu, S; Wong, SQ; Gasi Tandefelt, D; Conteduca, V; Wetterskog, D; Attard, G; Lise, S (2019-08-02)

  BACKGROUND: Targeted deep sequencing is a highly effective technology to identify known and novel single nucleotide variants (SNVs) with many applications in translational medicine, disease monitoring and cancer profiling. ...
• A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. 

  Connell, SP; Hanna, M; McCarthy, F; Hurst, R; Webb, M; Curley, H; Walker, H; Mills, R; Ball, RY; Sanda, MG; Pellegrini, KL; Patil, D; Perry, AS; Schalken, J; Pandha, H; Whitaker, H; Dennis, N; Stuttle, C; Mills, IG; Guldvik, I; Movember GAP1 Urine Biomarker Consortium; Parker, C; Brewer, DS; Cooper, CS; Clark, J (2019-05-20)

  OBJECTIVES: To develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of providing diagnostic information of disease status prior to biopsy, and prognostic information for men on active ...
• Comparison of TRUS-Biopsy to Transperineal Template Mapping Biopsies Stratified by Multi-Parametric MRI Score within the PROMIS Trial. 

  Lovegrove, C; Miah, S; El-Shater Bosaily, A; Bott, S; Brown, L; Burns-Cox, N; Dudderidge, T; Freeman, A; Henderson, A; Hindley, R; Kaplan, R; Kirkham, A; Oldroyd, R; Parker, C; Persad, R; Punwani, S; Rosario, D; Shergill, I; Winkler, M; Emberton, M; Ahmed, HU (2019-07-23)

  INTRODUCTION: We evaluated performance of transrectal ultrasound-guided systematic (TRUS) biopsy compared to transperineal template mapping (TPM) with a 5mm sampling frame, stratified by MP-MRI Likert score within the ...
• Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. 

  Madariaga, A; Rustin, GJS; Buckanovich, RJ; Trent, JC; Oza, AM (2019-01)

  Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the ...
• Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. 

  Parker, C (2018)
• Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. 

  Brown, LC; Ahmed, HU; Faria, R; El-Shater Bosaily, A; Gabe, R; Kaplan, RS; Parmar, M; Collaco-Moraes, Y; Ward, K; Hindley, RG; Freeman, A; Kirkham, A; Oldroyd, R; Parker, C; Bott, S; Burns-Cox, N; Dudderidge, T; Ghei, M; Henderson, A; Persad, R; Rosario, DJ; Shergill, I; Winkler, M; Soares, M; Spackman, E; Sculpher, M; Emberton, M (2018-07)

  BACKGROUND: Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric ...
• The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? 

  Patel, PH; Palma, D; McDonald, F; Tree, AC (2019-06-07)

  Oligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled widespread disease. In the era of well-tolerated targeted treatments, ...
• This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. 

  Schiavone, F; Bathia, R; Letchemanan, K; Masters, L; Amos, C; Bara, A; Brown, L; Gilson, C; Pugh, C; Atako, N; Hudson, F; Parmar, M; Langley, R; Kaplan, RS; Parker, C; Attard, G; Clarke, NW; Gillessen, S; James, ND; Maughan, T; Sydes, MR; past and present members of the STAMPEDE and FOCUS4 Trial Management Group (2019-05-29)

  BACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons ...
• A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. 

  Verbeek, JFM; Nieboer, D; Parker, C; Kattan, MW; Steyerberg, EW; Roobol, MJ (2019-04-22)

  Prostate cancer (PCa) testing involves a complex individually based decision making process. It should consider competing risks from other comorbidities when estimating a survival benefit from the early detection of ...
• Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. 

  Gulley, JL; Borre, M; Vogelzang, NJ; Ng, S; Agarwal, N; Parker, CC; Pook, DW; Rathenborg, P; Flaig, TW; Carles, J; Saad, F; Shore, ND; Chen, L; Heery, CR; Gerritsen, WR; Priou, F; Langkilde, NC; Novikov, A; Kantoff, PW (2019-05-01)

  PURPOSE: PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further ...
• Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. 

  Burdett, S; Boevé, LM; Ingleby, FC; Fisher, DJ; Rydzewska, LH; Vale, CL; van Andel, G; Clarke, NW; Hulshof, MC; James, ND; Parker, CC; Parmar, MK; Sweeney, CJ; Sydes, MR; Tombal, B; Verhagen, PC; Tierney, JF; STOPCAP M1 Radiotherapy Collaborators (2019-07)

  BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: ...
• Proteomic navigation using proximity-labeling. 

  Gentzel, M; Pardo, M; Subramaniam, S; Stewart, AF; Choudhary, JS (2019-07-15)

  The identification of bona fide protein-protein interactions and the mapping of proteomes was greatly enhanced by protein tagging for generic affinity purification methods and analysis by mass spectrometry (AP-MS). The ...
• MUTYH-Associated Polyposis: The Irish Experience>. 

  McVeigh, TP; Duff, M; Carroll, C; O'Shea, R; Bradley, L; Farrell, M; Gallagher, DJ; Clabby, C; Green, AJ (2016-12-12)

  MUTYH is involved in DNA damage repair. Bi-allelic MUTYH mutations predispose to polyposis and gastrointestinal malignancies, distinct genetically from autosomal dominant familial adenomatous polyposis coli. Two common ...
• Pazopanib in advanced soft tissue sarcomas. 

  Lee, ATJ; Jones, RL; Huang, PH (2019)

  Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...

View more